Sep 13, 2025
1:00 PM2:00 PM
Poster Session
P057 - COST-EFFECTIVENESS AND CLINICAL OUTCOMES OF READY-TO-USE VS. COMPOUNDED PARENTERAL NUTRITION IN CRITICALLY ILL PATIENTS
P057
COST-EFFECTIVENESS AND CLINICAL OUTCOMES OF READY-TO-USE VS. COMPOUNDED PARENTERAL NUTRITION IN CRITICALLY ILL PATIENTS
D. Oliveira Toledo1,*, G. B. Yacoub 1, F. A. Ribeiro1, J. R. Moraes1, J. M. Silva Jr 1
1Clinical Nutrition, Hospital Israelita Albert Einstein, São Paulo, Brazil
Rationale: Critically ill patients often require parenteral nutrition (PN), but the clinical and economic impact of ready-to-use versus compounded PN remains unclear. This study aimed to compare the cost-effectiveness, safety, and clinical outcomes of these two PN strategies.
Methods: A prospective observational study was conducted in a tertiary hospital. Adult patients (≥18 years) requiring PN for at least three days were included and allocated into two groups: ready-to-use PN (RTU-PN) and compounded PN (C-PN). Data on nutritional composition, costs, complications, and mortality were collected. Primary outcomes included cost per avoided complication and cost per life saved.
Results: Fifty patients were analyzed (25 per group). C-PN provided higher protein intake (107.0 vs. 88.7 g/day; p=0.018), which was associated with higher urea levels (89.41 mg/dL vs. 48.32 mg/dL; p=0.002). No significant differences were observed in overall complication rates between groups (78.0% vs. 60.0%; p=0.09) or in hospital mortality (32.0% vs. 4.0%; p=0.34). Total costs were USD 129,919.00 for RTU-PN and USD 331,525.00 for C-PN, with an incremental cost of USD 201,606.00 over 25 days. The cost per avoided complication was USD 11,121.07 (RTU-PN) vs. USD 12,730.54 (C-PN), while the cost per life saved was USD 727.55 and USD 4,243.51, respectively.
Conclusion: C-PN resulted in significantly higher costs with no statistically significant difference in complications or mortality compared to RTU-PN. These findings suggest that RTU-PN may be a more cost-effective option without compromising patient safety.
Disclosure of Interest: None declared